

Citations

1. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. *Biochem Pharmacol* 2006;71:1397-1421.
2. Khan N, Afaq F, Saleem M et al. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. *Cancer Res* 2006;66:2500-2505.
3. Na H-K, Surh Y-J. Intracellular signaling network as a prime chemopreventive target of (-)-epigallocatechin gallate. *Mol Nutr Food Res* 2006;50:152-159.
4. Yang CS, Sang S, Lambert JD et al. Possible mechanisms of the cancer-preventive activities of green tea. *Mol Nutr Food Res* 2006;50:170-175.
5. McKenna D, Jones K, Hughes K, Humphrey S. Green tea. *Botanical Medicines*. 2nd ed. Binghamton, NY: Haworth Press; 2002:223-254.
6. Stockley I. *Stockley's Drug Interactions*. 6th ed. London: Pharmaceutical Press; 2002.
7. Huang MT, Xie JG, Wang ZY et al. Effects of tea, decaffeinated tea, and caffeine on UVB light-induced complete carcinogenesis in SKH-1 mice: demonstration of caffeine as a biologically important constituent of tea. *Cancer Res* 1997;57:2623-2629.
8. Conney AH, Lu YP, Lou YR, Huang MT. Inhibitory effects of tea and caffeine on UV-induced carcinogenesis: relationship to enhanced apoptosis and decreased tissue fat. *Eur J Cancer Prev* 2002;11 Suppl 2:S28-36.
9. Lu YP, Lou YR, Lin Y et al. Inhibitory effects of orally administered green tea, black tea, and caffeine on skin carcinogenesis in mice previously treated with ultraviolet B light (high-risk mice): relationship to decreased tissue fat. *Cancer Res* 2001;61:5002-5009.
10. Beecher GR. Overview of dietary flavonoids: nomenclature, occurrence and intake. *J Nutr* 2003;133:3248S-3254S.
11. Seely D, Mills EJ, Wu P et al. The effects of green tea consumption on incidence of breast cancer and recurrence of breast cancer: a systematic review and meta-analysis. *Integr Cancer Ther* 2005;4:144-155.
12. Jodoin J, Demeule M, Beliveau R. Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. *Biochim Biophys Acta* 2002;1542:149-159.
13. Chow HH, Cai Y, Alberts DS et al. Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. *Cancer Epidemiol Biomarkers Prev* 2001;10:53-58.
14. Lambert JD, Yang CS. Cancer chemopreventive activity and bioavailability of tea and tea polyphenols. *Mutat Res* 2003;523-524:201-208.
15. Vaidyanathan JB, Walle T. Glucuronidation and sulfation of the tea flavonoid (-)-epicatechin by the human and rat enzymes. *Drug Metab Dispos* 2002;30:897-903.
16. Hong J, Lu H, Meng X et al. Stability, cellular uptake, biotransformation, and efflux of tea polyphenol (-)-epigallocatechin-3-gallate in HT-29 human colon adenocarcinoma cells. *Cancer Res* 2002;62:7241-7246.
17. Hou Z, Lambert JD, Chin KV, Yang CS. Effects of tea polyphenols on signal transduction pathways related to cancer chemoprevention. *Mutat Res* 2004;555:3-19.
18. Maliakal PP, Coville PF, Wanwimolruk S. Tea consumption modulates hepatic drug metabolizing enzymes in Wistar rats. *J Pharm Pharmacol* 2001;53:569-577.
19. Maliakal PP, Wanwimolruk S. Effect of herbal teas on hepatic drug metabolizing enzymes in rats. *J Pharm Pharmacol* 2001;53:1323-1329.
20. Feng Q, Torii Y, Uchida K et al. Black tea polyphenols, theaflavins, prevent cellular DNA damage by inhibiting oxidative stress and suppressing cytochrome P450 1A1 in cell cultures. *J Agric Food Chem* 2002;50:213-220.
21. Williams SN, Pickwell GV, Quattrochi LC. A combination of tea (*Camellia senensis*) catechins is required for optimal inhibition of induced CYP1A expression by green tea extract. *J Agric Food Chem* 2003;51:6627-6634.
22. Krishnan R, Maru GB. Inhibitory effect(s) of polymeric black tea polyphenol fractions on the formation of [(3)H]-B(a)P-derived DNA adducts. *J Agric Food Chem* 2004;52:4261-4269.
23. Krishnan R, Raghunathan R, Maru GB. Effect of polymeric black tea polyphenols on benzo(a)pyrene [B(a)P]-induced cytochrome P4501A1 and 1A2 in mice. *Xenobiotica* 2005;35:671-682.
24. Muto S, Fujita K, Yamazaki Y, Kamataki T. Inhibition by green tea catechins of metabolic activation of procarcinogens by human cytochrome P450. *Mutat Res* 2001;479:197-206.
25. Niwattisaiwong N, Luo XX, Coville PF, Wanwimolruk S. Effects of Chinese, Japanese and Western tea on hepatic P450 enzyme activities in rats. *Drug Metabol Drug Interact* 2004;20:43-56.
26. Bu-Abbas A, Clifford MN, Ioannides C, Walker R. Stimulation of rat hepatic UDP-glucuronosyl transferase activity following treatment with green tea. *Food Chem Toxicol* 1995;33:27-30.

Citations and Reference Literature: Green Tea

27. Bu-Abbas A, Clifford MN, Walker R, Ioannides C. Contribution of caffeine and flavanols in the induction of hepatic Phase II activities by green tea. *Food Chem Toxicol* 1998;36:617-621.
28. Xu M, Dashwood RH. Chemoprevention studies of heterocyclic amine-induced colon carcinogenesis. *Cancer Lett* 1999;143:179-183.
29. Embola CW, Sohn OS, Fiala ES, Weisburger JH. Induction of UDP-glucuronosyltransferase 1 (UDP-GT1) gene complex by green tea in male F344 rats. *Food Chem Toxicol* 2002;40:841-844.
30. Moyers SB, Kumar NB. Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials. *Nutr Rev* 2004;62:204-211.
31. Zhong Z, Connor HD, Froh M et al. Polyphenols from *Camellia sinensis* prevent primary graft failure after transplantation of ethanol-induced fatty livers from rats. *Free Radic Biol Med* 2004;36:1248-1258.
32. Nishimuta H, Tsujimoto M, Ogura K et al. Inhibitory effects of various beverages on ritodrine sulfation by recombinant human sulfotransferase isoforms SULT1A1 and SULT1A3. *Pharm Res* 2005;22:1406-1410.
33. Wang EJ, Barecki-Roach M, Johnson WW. Elevation of P-glycoprotein function by a catechin in green tea. *Biochem Biophys Res Commun* 2002;297:412-418.
34. Zhu A, Wang X, Guo Z. Study of tea polyphenol as a reversal agent for carcinoma cell lines' multidrug resistance (study of TP as a MDR reversal agent). *Nucl Med Biol* 2001;28:735-740.
35. Sadzuka Y, Sugiyama T, Sonobe T. Efficacies of tea components on doxorubicin-induced antitumor activity and reversal of multidrug resistance. *Toxicol Lett* 2000;114:155-162.
36. Kitagawa S, Nabekura T, Kamiyama S. Inhibition of P-glycoprotein function by tea catechins in KB-C2 cells. *J Pharm Pharmacol* 2004;56:1001-1005.
37. Lee K, Ng C, Brouwer KL, Thakker DR. Secretory transport of ranitidine and famotidine across Caco-2 cell monolayers. *J Pharmacol Exp Ther* 2002;303:574-580.
38. Mei Y, Qian F, Wei D, Liu J. Reversal of cancer multidrug resistance by green tea polyphenols. *J Pharm Pharmacol* 2004;56:1307-1314.
39. Vaidyanathan JB, Walle T. Transport and metabolism of the tea flavonoid (–)-epicatechin by the human intestinal cell line Caco-2. *Pharm Res* 2001;18:1420-1425.
40. Vaidyanathan JB, Walle T. Cellular uptake and efflux of the tea flavonoid (–)-epicatechin-3-gallate in the human intestinal cell line Caco-2. *J Pharmacol Exp Ther* 2003;307:745-752.
41. Fuchikami H, Satoh H, Tsujimoto M et al. Effects of herbal extracts on the function of human organic anion transporting polypeptide, OATP-B. *Drug Metab Dispos* 2006;34:577-582.
42. Netsch MI, Gutmann H, Luescher S et al. Inhibitory activity of a green tea extract and some of its constituents on multidrug resistance-associated protein 2 functionality. *Planta Med* 2005;71:135-141.
43. Sadzuka Y, Yamashita Y, Kishimoto S et al. [Glutamate transporter-mediated increase of antitumor activity by theanine, an amino acid in green tea]. *Yakugaku Zasshi* 2002;122:995-999.
44. Sugiyama T, Sadzuka Y, Tanaka K, Sonobe T. Inhibition of glutamate transporter by theanine enhances the therapeutic efficacy of doxorubicin. *Toxicol Lett* 2001;121:89-96.
45. Sugiyama T, Sadzuka Y. Theanine and glutamate transporter inhibitors enhance the antitumor efficacy of chemotherapeutic agents. *Biochim Biophys Acta* 2003;1653:47-59.
46. Sugiyama T, Sadzuka Y. Theanine, a specific glutamate derivative in green tea, reduces the adverse reactions of doxorubicin by changing the glutathione level. *Cancer Lett* 2004;212:177-184.
47. Uehara M, Sugiura H, Sakurai K. A trial of oolong tea in the management of recalcitrant atopic dermatitis. *Arch Dermatol* 2001;137:42-43.
48. Furue M, Terao H, Moroi Y et al. Dosage and adverse effects of topical tacrolimus and steroids in daily management of atopic dermatitis. *J Dermatol* 2004;31:277-283.
49. Sadzuka Y, Sugiyama T, Miyagishima A et al. The effects of theanine, as a novel biochemical modulator, on the antitumor activity of Adriamycin. *Cancer Lett* 1996;105:203-209.
50. Sadzuka Y, Sugiyama T, Hirota S. Modulation of cancer chemotherapy by green tea. *Clin Cancer Res* 1998;4:153-156.
51. Sugiyama T, Sadzuka Y. Combination of theanine with doxorubicin inhibits hepatic metastasis of M5076 ovarian sarcoma. *Clin Cancer Res* 1999;5:413-416.
52. Hrelia S, Bordonni A, Angeloni C et al. Green tea extracts can counteract the modification of fatty acid composition induced by doxorubicin in cultured cardiomyocytes. *Prostaglandins Leukot Essent Fatty Acids* 2002;66:519-524.
53. Samman S, Sandstrom B, Toft MB et al. Green tea or rosemary extract added to foods reduces nonheme-iron absorption. *Am J Clin Nutr* 2001;73:607-612.

Citations and Reference Literature: Green Tea

54. Temme EH, Van Hoydonck PG. Tea consumption and iron status. *Eur J Clin Nutr* 2002;56:379-386.
55. Nelson M, Poulter J. Impact of tea drinking on iron status in the UK: a review. *J Hum Nutr Diet* 2004;17:43-54.
56. Merhav H, Amitai Y, Palti H, Godfrey S. Tea drinking and microcytic anemia in infants. *Am J Clin Nutr* 1985;41:1210-1213.
57. Zijp IM, Korver O, Tijburg LB. Effect of tea and other dietary factors on iron absorption. *Crit Rev Food Sci Nutr* 2000;40:371-398.
58. Shiota S, Shimizu M, Mizushima T et al. Marked reduction in the minimum inhibitory concentration (MIC) of beta-lactams in methicillin-resistant *Staphylococcus aureus* produced by epicatechin gallate, an ingredient of green tea (*Camellia sinensis*). *Biol Pharm Bull* 1999;22:1388-1390.
59. Hu ZQ, Zhao WH, Hara Y, Shimamura T. Epigallocatechin gallate synergy with ampicillin/sulbactam against 28 clinical isolates of methicillin-resistant *Staphylococcus aureus*. *J Antimicrob Chemother* 2001;48:361-364.
60. Hu ZQ, Zhao WH, Asano N et al. Epigallocatechin gallate synergistically enhances the activity of carbapenems against methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2002;46:558-560.
61. Zhao WH, Hu ZQ, Okubo S et al. Mechanism of synergy between epigallocatechin gallate and beta-lactams against methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2001;45:1737-1742.
62. Sudano Roccaro A, Blanco AR, Giuliano F et al. Epigallocatechin-gallate enhances the activity of tetracycline in staphylococci by inhibiting its efflux from bacterial cells. *Antimicrob Agents Chemother* 2004;48:1968-1973.
63. Zhao WH, Hu ZQ, Hara Y, Shimamura T. Inhibition of penicillinase by epigallocatechin gallate resulting in restoration of antibacterial activity of penicillin against penicillinase-producing *Staphylococcus aureus*. *Antimicrob Agents Chemother* 2002;46:2266-2268.
64. Kajiya K, Kumazawa S, Nakayama T. Effects of external factors on the interaction of tea catechins with lipid bilayers. *Biosci Biotechnol Biochem* 2002;66:2330-2335.
65. Caturla N, Vera-Samper E, Villalain J et al. The relationship between the antioxidant and the antibacterial properties of galloylated catechins and the structure of phospholipid model membranes. *Free Radic Biol Med* 2003;34:648-662.
66. Stapleton PD, Shah S, Anderson JC et al. Modulation of beta-lactam resistance in *Staphylococcus aureus* by catechins and gallates. *Int J Antimicrob Agents* 2004;23:462-467.
67. Hirasawa M, Takada K. Multiple effects of green tea catechin on the antifungal activity of antimycotics against *Candida albicans*. *J Antimicrob Chemother* 2004;53:225-229.
68. Yanagawa Y, Yamamoto Y, Hara Y, Shimamura T. A combination effect of epigallocatechin gallate, a major compound of green tea catechins, with antibiotics on *Helicobacter pylori* growth in vitro. *Curr Microbiol* 2003;47:244-249.
69. Isogai E, Isogai H, Hirose K et al. In vivo synergy between green tea extract and levofloxacin against enterohemorrhagic *Escherichia coli* O157 infection. *Curr Microbiol* 2001;42:248-251.
70. Tiwari TP, Bharti SK, Kaur HD et al. Synergistic antimicrobial activity of tea and antibiotics. *Indian J Med Res* 2005;122:80-84.
71. Hu ZQ, Zhao WH, Yoda Y et al. Additive, indifferent and antagonistic effects in combinations of epigallocatechin gallate with 12 non-beta-lactam antibiotics against methicillin-resistant *Staphylococcus aureus*. *J Antimicrob Chemother* 2002;50:1051-1054.
72. Lee YS, Han CH, Kang SH et al. Synergistic effect between catechin and ciprofloxacin on chronic bacterial prostatitis rat model. *Int J Urol* 2005;12:383-389.
73. Yamada H, Ohashi K, Atsumi T et al. Effects of tea catechin inhalation on methicillin-resistant *Staphylococcus aureus* in elderly patients in a hospital ward. *J Hosp Infect* 2003;53:229-231.
74. Suganuma M, Okabe S, Kai Y et al. Synergistic effects of (–)-epigallocatechin gallate with (–)-epicatechin, sulindac, or tamoxifen on cancer-preventive activity in the human lung cancer cell line PC-9. *Cancer Res* 1999;59:44-47.
75. Suganuma M, Sueoka E, Sueoka N et al. Mechanisms of cancer prevention by tea polyphenols based on inhibition of TNF- α expression. *Biofactors* 2000;13:67-72.
76. Way TD, Lee HH, Kao MC, Lin JK. Black tea polyphenol theaflavins inhibit aromatase activity and attenuate tamoxifen resistance in HER2/neu-transfected human breast cancer cells through tyrosine kinase suppression. *Eur J Cancer* 2004;40:2165-2174.
77. Satoh K, Sakamoto Y, Ogata A et al. Inhibition of aromatase activity by green tea extract catechins and their endocrinological effects of oral administration in rats. *Food Chem Toxicol* 2002;40:925-933.
78. El-Beshbishy HA. Hepatoprotective effect of green tea (*Camellia sinensis*) extract against tamoxifen-induced liver injury in rats. *J Biochem Mol Biol* 2005;38:563-570.
79. De Jong PC, Blankenstein MA, van de Ven J et al. Importance of local aromatase activity in hormone-dependent breast cancer: a review. *Breast* 2001;10:91-99.
80. Zhang X, Wang LY, Jiang TY et al. Effects of testosterone and 17- β -estradiol on TNF- α -induced E-selectin and VCAM-1 expression in endothelial cells: analysis of the underlying receptor pathways. *Life Sci* 2002;71:15-29.
81. Lambert JD, Yang CS. Mechanisms of cancer prevention by tea constituents. *J Nutr* 2003;133:3262S-3267S.

Citations and Reference Literature: Green Tea

82. Bode AM, Dong Z. Targeting signal transduction pathways by chemopreventive agents. *Mutat Res* 2004;555:33-51.
83. Dorai T, Aggarwal BB. Role of chemopreventive agents in cancer therapy. *Cancer Lett* 2004;215:129-140.
84. Liang YC, Lin-shiau SY, Chen CF, Lin JK. Suppression of extracellular signals and cell proliferation through EGF receptor binding by (-)-epigallocatechin gallate in human A431 epidermoid carcinoma cells. *J Cell Biochem* 1997;67:55-65.
85. Masuda M, Suzui M, Weinstein IB. Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. *Clin Cancer Res* 2001;7:4220-4229.
86. Masuda M, Suzui M, Lim JT, Weinstein IB. Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells. *Clin Cancer Res* 2003;9:3486-3491.
87. Shimizu M, Deguchi A, Joe AK et al. EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells. *J Exp Ther Oncol* 2005;5:69-78.
88. Suter TM, Cook-Bruns N, Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. *Breast* 2004;13:173-183.
89. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. *J Clin Oncol* 2004;22:322-329.
90. Kang WS, Lim IH, Yuk DY et al. Antithrombotic activities of green tea catechins and (-)-epigallocatechin gallate. *Thromb Res* 1999;96:229-237.
91. Sagesaka-Mitane Y, Miwa M, Okada S. Platelet aggregation inhibitors in hot water extract of green tea. *Chem Pharm Bull (Tokyo)* 1990;38:790-793.
92. Son DJ, Cho MR, Jin YR et al. Antiplatelet effect of green tea catechins: a possible mechanism through arachidonic acid pathway. *Prostaglandins Leukot Essent Fatty Acids* 2004;71:25-31.
93. Duffy SJ, Vita JA, Holbrook M et al. Effect of acute and chronic tea consumption on platelet aggregation in patients with coronary artery disease. *Arterioscler Thromb Vasc Biol* 2001;21:1084-1089.
94. Wolfram RM, Oguogho A, Efthimiou Y et al. Effect of black tea on (iso-)prostaglandins and platelet aggregation in healthy volunteers. *Prostaglandins Leukot Essent Fatty Acids* 2002;66:529-533.
95. Hodgson JM, Puddey IB, Mori TA et al. Effects of regular ingestion of black tea on haemostasis and cell adhesion molecules in humans. *Eur J Clin Nutr* 2001;55:881-886.
96. Hodgson JM, Puddey IB, Burke V et al. Acute effects of ingestion of black tea on postprandial platelet aggregation in human subjects. *Br J Nutr* 2002;87:141-145.
97. Taylor JR, Wilt VM. Probable antagonism of warfarin by green tea. *Ann Pharmacother* 1999;33:426-428.
98. Booth SL, Madabushi HT, Davidson KW, Sadowski JA. Tea and coffee brews are not dietary sources of vitamin K-1 (phylloquinone). *J Am Diet Assoc* 1995;95:82-83.